Clinical Trial Update: PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating a PET imaging agent targeting phosphodiesterase-4 (PDE4) in volunteers including individuals with Alzheimer's disease a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Snippet

Sponsor: National Institute of Mental Health (NIMH) | Conditions: Alzheimer s Disease, Mild Cognitive Impairment | Phase 1 | Status: RECRUITING